<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02793687</url>
  </required_header>
  <id_info>
    <org_study_id>2013-08-11</org_study_id>
    <nct_id>NCT02793687</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of MEXIDOL®</brief_title>
  <official_title>Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of the Drug MEXIDOL® for a Long Sequence of Therapy in Patients With Hemispheric Ischemic Stroke in the Acute and Early Recovery Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmasoft</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmasoft</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, prospective, randomized, double-blind, placebo-controlled, parallel group&#xD;
      study in patients with stroke&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin Scale</measure>
    <time_frame>5 times during 67-71 days of the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The National Institutes of Health Stroke Scale</measure>
    <time_frame>5 times during 67-71 days of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>5 times during 67-71 days of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory</measure>
    <time_frame>5 times during 67-71 days of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL Quality of Life Scale</measure>
    <time_frame>5 times during 67-71 days of the treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Mexidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.&#xD;
The use of the study drug is held with basic therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sequential therapy as follows: Placebo (i.v. solution) for 10 days followed by placebo 1 tablet three times a day for 8 weeks.&#xD;
The use of a placebo is held with basic therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEXIDOL® (ethylmethylhydroxypyridine succinate)</intervention_name>
    <arm_group_label>Mexidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis: hemispheric ischemic stroke (codes ICD-10: I63.0 - I63.9), primary.&#xD;
&#xD;
          2. Patients of both sexes, from 40 to 80 years.&#xD;
&#xD;
          3. Patients who are able to understand the purpose of this study and observe the&#xD;
             requirements of the Protocol;&#xD;
&#xD;
          4. The time from onset of stroke - not more than 72 hours.&#xD;
&#xD;
          5. Based on the Rankin Scale score of 3 points or more at the time of enrollment.&#xD;
&#xD;
          6. Evaluation of NIHSS scale from 5 to 15 points.&#xD;
&#xD;
          7. Based on the depression scale Beck &lt;19 points&#xD;
&#xD;
          8. Have personally signed and dated by the patient (or otherwise disinterested witness&#xD;
             who is not a member of the research team and is not in direct subordinate to the&#xD;
             principal investigator, in the absence of physical possibility of signing the patient)&#xD;
             informed consent form.&#xD;
&#xD;
          9. Have a negative pregnancy test for women of childbearing age.&#xD;
&#xD;
         10. Consent to use adequate contraception female patients and / or willingness to use&#xD;
             contraception female partners of male patients or abstinence from sexual activity for&#xD;
             the period of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of diagnosis: hemispheric ischemic stroke (codes ICD-10: I63.0 - I63.9), primary.&#xD;
&#xD;
          2. Age &lt;40 and&gt; 80 years.&#xD;
&#xD;
          3. Assessment of the scale NIHSS &lt;5 or&gt; 15 points&#xD;
&#xD;
          4. Hemorrhagic stroke (confirmed with imaging techniques (CT or MRI).&#xD;
&#xD;
          5. Hemorrhagic infarction (ischemic stroke with hemorrhagic impregnation).&#xD;
&#xD;
          6. Repeated ischemic stroke.&#xD;
&#xD;
          7. Parkinson's disease.&#xD;
&#xD;
          8. Epilepsy.&#xD;
&#xD;
          9. Demyelinating disease of the nervous system.&#xD;
&#xD;
         10. hereditary degenerative diseases of the CNS.&#xD;
&#xD;
         11. The presence of CNS infectious diseases in history.&#xD;
&#xD;
         12. Traumatic brain injury with severe neurological symptoms and cognitive disorders&#xD;
             (including history).&#xD;
&#xD;
         13. Unstable angina pectoris.&#xD;
&#xD;
         14. Myocardial infarction, prescription of less than 3 months.&#xD;
&#xD;
         15. Chronic heart failure functional class IV according to the classification of the New&#xD;
             York Heart Association (NYHA).&#xD;
&#xD;
         16. atrioventricular block degree II-III.&#xD;
&#xD;
         17. Systemic connective tissue diseases.&#xD;
&#xD;
         18. Chronic obstructive pulmonary stage III-IV disease.&#xD;
&#xD;
         19. Acute surgical pathology.&#xD;
&#xD;
         20. Heavy, decompensated heart disease, liver, kidney, acute / chronic renal / hepatic&#xD;
             failure.&#xD;
&#xD;
         21. A history of cancer, immunosuppressive conditions, tuberculosis, drug or alcohol&#xD;
             addiction, mental illness.&#xD;
&#xD;
         22. A history of any material, according to a research physician, state, prevents the&#xD;
             inclusion in the study.&#xD;
&#xD;
         23. Acute infectious diseases (influenza, SARS, etc.) In less than 4 weeks before the&#xD;
             start of the study.&#xD;
&#xD;
         24. Availability of information on lactose intolerance / congenital galactose intolerance;&#xD;
             Lapp lactase deficiency or glucose-galactose syndrome malabsorption.&#xD;
&#xD;
         25. Pregnancy, lactation.&#xD;
&#xD;
         26. Mental, physical or other reasons that do not allow to adequately assess their&#xD;
             behavior and comply with the terms of the protocol correctly.&#xD;
&#xD;
         27. Patients who are employees of the research center, the sponsoring company, as well as&#xD;
             their family members.&#xD;
&#xD;
         28. Participation in a clinical trial of drugs in less than 3 months prior to the study.&#xD;
&#xD;
         29. Any other conditions and circumstances make it difficult, according to the researcher,&#xD;
             participated in the study.&#xD;
&#xD;
         30. Individual intolerance emoxypine, as well as preparations containing a salt of&#xD;
             succinic acid and vitamin B6 in history.&#xD;
&#xD;
         31. The presence of any contraindications to the use of the drug MEXIDOL®&#xD;
&#xD;
         32. No personally signed and dated by the patient (or otherwise disinterested witness in&#xD;
             the absence of physical possibility of signing the patient) informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emoxypine succinate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 10, 2021</submitted>
    <returned>April 5, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

